Tenax Therapeutics Inc (TENX) - Total Liabilities
Based on the latest financial reports, Tenax Therapeutics Inc (TENX) has total liabilities worth $8.07 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore TENX long-term investment intensity to see how much of total assets are deployed in long-term investments.
Tenax Therapeutics Inc - Total Liabilities Trend (1995–2025)
This chart illustrates how Tenax Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Tenax Therapeutics Inc.
Tenax Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Tenax Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Grupe S.A.B. de C.V
MX:CIDMEGA
|
Mexico | MX$4.24 Billion |
|
Kronox Lab Sciences Ltd
NSE:KRONOX
|
India | Rs113.96 Million |
|
Thai Mitsuwa Public Company Limited
BK:TMW
|
Thailand | ฿805.63 Million |
|
Manuka Resources Ltd
AU:MKR
|
Australia | AU$38.06 Million |
|
Union Auction Public Company Limited
BK:AUCT
|
Thailand | ฿1.31 Billion |
|
Optex Systems Holdings, Inc. Common Stock
NASDAQ:OPXS
|
USA | $4.74 Million |
|
Bubs Australia Ltd
AU:BUB
|
Australia | AU$24.72 Million |
|
Ching Chan Optical Technology Co Ltd
TWO:2070
|
Taiwan | NT$574.88 Million |
Liability Composition Analysis (1995–2025)
This chart breaks down Tenax Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See TENX net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tenax Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tenax Therapeutics Inc (1995–2025)
The table below shows the annual total liabilities of Tenax Therapeutics Inc from 1995 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $7.16 Million | +52.48% |
| 2024-12-31 | $4.69 Million | +30.85% |
| 2023-12-31 | $3.59 Million | +87.58% |
| 2022-12-31 | $1.91 Million | +9.41% |
| 2021-12-31 | $1.75 Million | -22.09% |
| 2020-12-31 | $2.24 Million | -13.49% |
| 2019-12-31 | $2.59 Million | +65.60% |
| 2018-12-31 | $1.57 Million | +55.19% |
| 2017-12-31 | $1.01 Million | -83.73% |
| 2016-12-31 | $6.20 Million | -50.66% |
| 2015-12-31 | $12.56 Million | +19.15% |
| 2014-12-31 | $10.54 Million | 0.00% |
| 2013-12-31 | $10.54 Million | +190.04% |
| 2012-12-31 | $3.64 Million | -46.24% |
| 2011-12-31 | $6.76 Million | +382.26% |
| 2010-12-31 | $1.40 Million | +16.95% |
| 2009-12-31 | $1.20 Million | -33.10% |
| 2008-12-31 | $1.79 Million | -27.15% |
| 2007-12-31 | $2.46 Million | +479.35% |
| 2006-12-31 | $424.57K | +35.24% |
| 2005-12-31 | $313.94K | -13.16% |
| 2004-12-31 | $361.51K | +8.32% |
| 2003-12-31 | $333.75K | +309.28% |
| 2002-12-31 | $81.55K | -79.52% |
| 2001-12-31 | $398.09K | +15.24% |
| 2000-12-31 | $345.44K | -42.43% |
| 1999-12-31 | $600.00K | -5.42% |
| 1998-12-31 | $634.36K | +5.61% |
| 1997-12-31 | $600.67K | -39.42% |
| 1996-12-31 | $991.54K | 0.00% |
| 1995-12-31 | $991.54K | -- |
About Tenax Therapeutics Inc
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imat… Read more